What Have We Learned About GLP-1s?

Weight-loss drugs like Ozempic and Wegovy are one of the fastest growing pharmaceuticals. But as newer GLP-1 medications hit the market, questions remain about side effects, health equity and the cultural impact. On today’s In the Loop, we ask: what have we learned so far about the popular drug? And how have GLP-1s changed the way we think about health and weight loss?GUESTS: Dr. Micah Eimer, cardiologist, clinical assistant professor of medicine in the division of cardiology at Northwestern University Feinberg SchoolDavid D. Kim, PhD, assistant professor of medicine and public health sciences at University of ChicagoRachelle Lacroix Mallick, registered dietician and nutritionist with a focus on reproductive healthFor a full archive of In the Loop interviews, head over to wbez.org/intheloop.